# A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

> **NCT06697184** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **BeiGene** · enrollment: 56 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia
- CLL

## Interventions

- **DRUG:** Sonrotoclax
- **DRUG:** Zanubrutinib

## Key facts

- **NCT ID:** NCT06697184
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-01-23
- **Primary completion:** 2027-06
- **Final completion:** 2027-12-31
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2025-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06697184

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06697184, "A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06697184. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*